Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Human Albumin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    347 result(s) found for: Human Albumin. Displaying page 7 of 18.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2006-005993-39 Sponsor Protocol Number: IPR/16 Start Date*: 2007-04-26
    Sponsor Name:MOLMED
    Full Title: NGR010: A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than on...
    Medical condition: patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic therapeutic
    Disease: Version SOC Term Classification Code Term Level
    6.1 10035605 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002586-21 Sponsor Protocol Number: X04-MMRr-301 Start Date*: 2004-12-23
    Sponsor Name:Aventis Pasteur MSD SNC
    Full Title: An open, randomised, comparative, multicentre study of the immunogenicity and safety of M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX® when administered concomitantly by in...
    Medical condition: Not applicable - Healthy subjects
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001332-35 Sponsor Protocol Number: AX-CL-PANC-PI-0006859 Start Date*: 2017-03-20
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer
    Medical condition: Locally advanced pancreatic adenocarcinoma without distant metastases, according to the Dutch Pancreatic Cancer Group (DPCG) definition.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011437-27 Sponsor Protocol Number: MAFRI Start Date*: 2009-10-27
    Sponsor Name:Fundació Clínic
    Full Title: EFECTO DE LA ADMINISTRACIÓN DE ALBÚMINA INTRAVENOSA Y MIDODRINA ORAL SOBRE LA FUNCIÓN RENAL DE LOS PACIENTES CON CIRROSIS HEPÁTICA Y INSUFICIENCIA RENAL FUNCIONAL
    Medical condition: mejorar la disfunción circulatória en pacientes con cirrosis hepática
    Disease: Version SOC Term Classification Code Term Level
    9 10009213 Cirrhosis of liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001333-88 Sponsor Protocol Number: ACTION Start Date*: 2014-10-16
    Sponsor Name:Academic Medical Center
    Full Title: A phase Ib/II study on the addition of Nab-paclitaxel (Abraxane) to capecitabine and oxaliplatin in the first-line treatment of metastastasized oesophagogastric carcinoma
    Medical condition: Metastasized oesophagogastric carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011299-32 Sponsor Protocol Number: 20060359 Start Date*: 2010-08-06
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence
    Medical condition: Early-stage non-metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed) HU (Completed) GB (Completed) ES (Prematurely Ended) CZ (Completed) LV (Completed) FR (Completed) BE (Completed) SK (Completed) NL (Completed) IE (Prematurely Ended) DK (Completed) SI (Completed) GR (Completed) IT (Completed) BG (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000577-65 Sponsor Protocol Number: 2993-114 Start Date*: 2004-08-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, randomized, open label, comparator-controlled, parallel-group, multicentre study to compare the effects of exenatide and insulin glargine on beta cell function and cardiovascular risk ma...
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2016-002678-11 Sponsor Protocol Number: ICO-13-001 Start Date*: 2018-06-07
    Sponsor Name:Institut Català d’Oncologia
    Full Title: An open label biomarker pilot study of the antitumoral acrivity of denosumab in the pre-operative setting of early breast cancer
    Medical condition: early breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-002043-30 Sponsor Protocol Number: 2021-06 Start Date*: 2022-01-13
    Sponsor Name:Assistance Publique Hôpitaux de Marseille
    Full Title: NOVEL TREATMENT OF DIABETIC FOOT ULCER BY AUTOLOGOUS STROMAL VASCULAR FRACTION OF ADIPOSE TISSUE: PHASE II OPEN-ENDED, MULTI-CENTRE STUDY
    Medical condition: DIABETIC FOOT ULCER
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004723-36 Sponsor Protocol Number: 29BRC18.0275 Start Date*: 2019-09-18
    Sponsor Name:CHRU de Brest
    Full Title: TEP/TDM pulmonaire de ventilation-perfusion au Gallium68 pour le diagnostic de l'embolie pulmonaire : une étude diagnostique versus angioscanner thoracique.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001503-10 Sponsor Protocol Number: 29/2006/O/Sper Start Date*: 2006-05-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Technology of the radioisotopes for the intra-operative identification of the sentinel node in the premature gastric cancer. Clinical study of feasibility in order to improve the treatment and prog...
    Medical condition: gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061968 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004155-67 Sponsor Protocol Number: PRIMUS0012016 Start Date*: 2017-08-01
    Sponsor Name:NHS Greater Glasgow and Clyde
    Full Title: PRIMUS 001 - An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker e...
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004156-29 Sponsor Protocol Number: PRIMUS0022016 Start Date*: 2018-08-13
    Sponsor Name:NHS Greater Glasgow and Clyde
    Full Title: PRIMUS 002: An umbrella phase II study examining two neo-adjuvant regimens (FOLFOX-A and AG) in resectable and borderline resectable Pancreatic Ductal Carcinoma (PDAC), focusing on biomarker and l...
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033608 Pancreatic cancer resectable LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-000341-19 Sponsor Protocol Number: 20050103 Start Date*: 2006-05-05
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer
    Medical condition: Metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) CZ (Completed) HU (Completed) ES (Completed) DE (Completed) NL (Completed) LT (Completed) SK (Completed) EE (Completed) SE (Completed) BE (Completed) LV (Completed) DK (Completed) IT (Completed) GR (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004250-13 Sponsor Protocol Number: HM-EXC-204 Start Date*: 2014-04-16
    Sponsor Name:Hanmi Pharmaceutical Co., Ltd.
    Full Title: A Phase II, 16-week, double-blind, placebo-controlled, parallel-group, randomised, multicentre trial to assess effect on glycaemic control of three doses of HM11260C in subjects with inadequately c...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004433-17 Sponsor Protocol Number: 124210 Start Date*: 2020-02-18
    Sponsor Name:MRC CTU at UCL
    Full Title: Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary arte...
    Medical condition: Kawasaki Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) EE (Completed) SE (Completed) FI (Completed) ES (Ongoing) DE (Completed) NL (Completed) IT (Completed) AT (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005485-37 Sponsor Protocol Number: 20050147 Start Date*: 2006-06-05
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer
    Medical condition: Castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) GB (Completed) CZ (Completed) BE (Completed) IE (Completed) SK (Completed) HU (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) LT (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-002032-26 Sponsor Protocol Number: BH 18387 Start Date*: 2004-12-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia
    Medical condition: Patient with chronic renal anaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) HU (Completed) DK (Completed) SE (Completed) CZ (Completed) NO (Completed) IT (Completed) DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003069-33 Sponsor Protocol Number: DS8201-A-U303 Start Date*: 2019-07-03
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: A phase 3, multicenter, randomized, open-label, active-controlled trial of trastuzumab deruxtecan (T-DXd), an anti-HER2-antibody drug conjugate (ADC), versus treatment of physician's choice for HER...
    Medical condition: Unresectable and/or metastatic breast cancer that is human epidermal growth factor receptor 2 (HER2)-low
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) IT (Completed) GR (Completed) PT (Completed) DE (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003775-20 Sponsor Protocol Number: HGT-MLD-071 Start Date*: 2013-09-11
    Sponsor Name:Shire Human Genetics Therapies Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    Full Title: An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy
    Medical condition: Treatment of Metachromatic Leukodystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10067609 Metachromatic leukodystrophy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 05:09:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA